Limited placental transfer and clearance of risankizumab by 6 months following in utero exposure

Christina Balmer

doi:10.1093/ecco-jcc/jjag086

Limited placental transfer and clearance of risankizumab by 6 months following in utero exposure

2026-06-25

0

PRE

AI

C

Christina Balmer *

J

Julie Korgaard

C

Charlotte Henneberg Holmboe

S

Signe Neldeborg

M

Mette Julsgaard

DOI：10.1093/ecco-jcc/jjag086

Original

Original request for help

Save

Abstract

En 中文

The recent Global Consensus supports the use of risankizumab during pregnancy. However, infant clearance following in utero exposure remains unknown, and data on placental transfer are scarce. We report on infant clearance following in utero exposure to risankizumab, and characterize placental transfer and infant outcomes.

Limited placental transfer and clearance of risankizumab by 6 months following in utero exposure

Abstract

Journal

Organization